Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats

Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats

“…Shang et al observed a significant decrease in SREBP-1 expression in the livers of rats that were fed a daily resveratrol dose of 100 mg/kg of body weight for 16 weeks [48]. It was reported that resveratrol treatment increased liver LDLR expression in rats [26]. In another study, after adding 0.0125% of resveratrol to the diet for 8 weeks, the expression level of PPARγ was significantly reduced in the livers of obese mice [49].…”

“…It was found that in HFD-fed Wistar rats, resveratrol (50 or 100 mg/kg/day) treatment for 13 weeks significantly suppressed body weight gain [26]. Andersen et al showed that resveratrol treatment (300 mg/kg/day) in male Wistar rats for 8 weeks decreased the fasting serum insulin level and insulin resistance [27].…”

“…First, the doses of resveratrol that were used in the animal experiments were very broad, ranging from 2.5 to 400 mg/kg/day [26,27,28,50]. We decided to choose the dose of 100 mg/kg/day because it is a middle and safe dose that was suggested by previous studies [ 26,27,28,50,51].…”

Hepatic scavenger receptor BI is associated with type 2 diabetes but unrelated to human and murine non-alcoholic fatty liver disease

“…These animals develop liver steatosis suggesting that SR-BI is not reduced in fatty liver. Twelve weeks high fat/high cholesterol diet nevertheless induces SR-BI mRNA expression [15] while reduced hepatic SR-BI has been described in Wistar rats fed a high fat/high sucrose diet for 13 weeks [16]. Feeding a cholesterol enriched diet has no effect on hepatic SR-BI in hamsters [12].…”

Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease

“…Its positive effects on animal NAFLD models have been shown in several studies. In different studies, Resveratrol decreased NAFLD severity in animal models in the following ways: through TNF-alpha inhibition and antioxidant activities [34] , through the activation of AMPK [35,36] , by induction of skeletal muscle SIRT1 and SIRT4 expression [37] , by increasing the number of mitochondria, and specially, by increasing hepatic uncoupling protein 2 expression [38] , decreasing hepatic LDL receptor and SR-BI mRNA and protein expressions [39] , and the reduction of nuclear factorkappaB (NF-kappaB) activity [40] . Clinical trials evaluating the effects of Resveratrol supplementation on NAFLD characteristics are scarce.…”